tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
VRTX is currently covered by 28 analysts with an average price target of $431.03. This is a potential upside of $36.86 (9.35%) from yesterday's end of day stock price of $394.17.
Vertex Pharmaceuticals's activity chart (see below) currently has 403 price targets and 390 ratings on display. The stock rating distribution of VRTX is 2.63% SELL, 64.04% BUY and 33.33% HOLD.
Analysts average stock forecasts to be materialized ratio is 90.79% with an average time for these price targets to be met of 226.83 days.
Highest price target for VRTX is $559, Lowest price target is $328, average price target is $431.03.
Most recent stock forecast was given by BRIAN ABRAHAMS from RBC on 06-Feb-2024. First documented stock forecast 29-May-2012.
8/24/00 2 for 1
Vertex Pharmaceuticals is a biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF), a genetic disease that affects the lungs and digestive system. Vertex founded in 1989 at Boston, Massachusetts.
Regulators have approved these medications for the treatment of patients aged 6 years or older with at least one F508del mutation.
The FDA has approved this medication for treating CF homozygous F508del mutation patients aged 2 years or older.
Which was approved by the U.S. Food and Drug Administration (FDA) in 2012. KALYDECO is a medication that is approved for treating CF patients who have a specific mutation that is responsive to ivacaftor.
In addition to these drugs, Vertex Pharmaceuticals has a pipeline of drugs in various stages of clinical development. VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, is currently in Phase 1 clinical trials. VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain, is in Phase 3 clinical trials. The company is also developing Exa-cel for the treatment of sickle cell disease and transfusion-dependent beta-thalassemia, which is in Phase 2/3 clinical trials, and VX-864 for the treatment of alpha-1 antitrypsin (AAT) deficiency, which is in Phase 2 clinical trials. The company is also developing drugs to treat cancer and other genetic diseases.
The company had also entered into collaborations with several biotechnology firms, such as CRISPR Therapeutics, Moderna, Entrada Therapeutics, Affinia Therapeutics, Arbor Biotechnologies, Kymera Therapeutics, Mammoth Biosciences, Obsidian Therapeutics, Verve Therapeutics, Skyhawk Therapeutics, and Ribometrix.
Vertex Pharmaceuticals’ contribution to treating CF has been recognized through its products. The FDA approved TRIKAFTA/KAFTRIO in 2018, and it was later approved in Europe in 2019.
The drug demonstrated significant improvement in lung function and quality of life in CF patients.
Currently out of the existing stock ratings of VRTX, 3 are a SELL (2.63%), 73 are a BUY (64.04%), 38 are a HOLD (33.33%).
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
420
$15.78 (3.90%)
397
2 months 13 days ago
27/33 (81.82%)
$3.87 (0.93%)
187
Buy
450
$45.78 (11.33%)
438
2 months 13 days ago
2/4 (50%)
$33.87 (8.14%)
89
Buy
457
$52.78 (13.06%)
397
2 months 13 days ago
15/16 (93.75%)
$40.87 (9.82%)
210
Buy
540
$135.78 (33.59%)
500
2 months 13 days ago
13/15 (86.67%)
$123.87 (29.77%)
331
Hold
438
$33.78 (8.36%)
436
2 months 13 days ago
5/6 (83.33%)
$21.87 (5.26%)
104
What is VRTX (Vertex Pharmaceuticals) average time for price targets to be met?
Which analyst has the current highest performing score on VRTX (Vertex Pharmaceuticals) with a proven track record?
Which analyst has the most public recommendations on VRTX (Vertex Pharmaceuticals)?
Which analyst is the currently most bullish on VRTX (Vertex Pharmaceuticals)?
Which analyst is the currently most reserved on VRTX (Vertex Pharmaceuticals)?
